Droplet digital PCR measurement of HER2 in patients with gastric cancer

被引：66

作者：

Kinugasa, H. ^{[1
]}

Nouso, K. ^{[1
,2
]}

Tanaka, T. ^{[3
]}

Miyahara, K. ^{[1
]}

Morimoto, Y. ^{[1
]}

Dohi, C. ^{[1
]}

Matsubara, T. ^{[4
]}

Okada, H. ^{[1
]}

Yamamoto, K. ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Dent & Pharmaceut Sci,Kita Ku, Okayama 7008558, Japan

[2] Okayama Univ, Grad Sch Med, Dept Mol Hepatol, Dent & Pharmaceut Sci,Kita Ku, Okayama 7008558, Japan

[3] Okayama Univ, Grad Sch Med, Dept Pathol, Dent & Pharmaceut Sci,Kita Ku, Okayama 7008558, Japan

[4] Okayama Univ Hosp, Innovat Clin Med, BioRepository BioMarker Anal Ctr, Kita Ku, Okayama 7008558, Japan

来源：

BRITISH JOURNAL OF CANCER | 2015年 / 112卷 / 10期

关键词：

Digital PCR; HER2; circulating tumour DNA; circulating DNA; ctDNA; gastric cancer; liquid biopsy; METASTATIC BREAST-CANCER; DNA; CHEMOTHERAPY; TRASTUZUMAB; PLASMA; SYSTEM; PLUS;

D O I：

10.1038/bjc.2015.129

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Although there are some new criteria for human epidermal growth factor receptor 2 (HER2) expression with immunohistochemistry/fluorescence in situ hybridisation (IHC/FISH) in gastric cancer, the method is still ambiguous and is somewhat dependent on the subjective qualities of the evaluator. Methods: We used droplet digital polymerase chain reaction (ddPCR) to evaluate HER2 amplification in formalin-fixed and paraffin-embedded (FFPE) samples and cell-free serum circulating tumour DNA (ctDNA) in 25 patients with gastric cancer. Results: The concordance rate of HER2 amplification examined in FFPE samples with ddPCR and IHC/FISH was 92% (23 out of 25). The concordance rate of FFPE with ctDNA was not high (62.5%); however, patients who were HER2-positive by ctDNA had significantly shorter survival compared with HER2-negative patients. Conclusions: Our results demonstrated that this ddPCR method was as effective as IHC/FISH and therefore might become a standard method for analysing not only FFPE but also ctDNA.

引用

页码：1652 / 1655

页数：4

共 17 条

[1] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

[2] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].

Cunningham, David ;

Allum, William H. ;

Stenning, Sally P. ;

Thompson, Jeremy N. ;

Van de Velde, Cornelis J. H. ;

Nicolson, Marianne ;

Scarffe, J. Howard ;

Lofts, Fiona J. ;

Falk, Stephen J. ;

Iveson, Timothy J. ;

Smith, David B. ;

Langley, Ruth E. ;

Verma, Monica ;

Weeden, Simon ;

Chua, Yu Jo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20

[3] Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer [J].

Dawson, Sarah-Jane ;

Tsui, Dana W. Y. ;

Murtaza, Muhammed ;

Biggs, Heather ;

Rueda, Oscar M. ;

Chin, Suet-Feung ;

Dunning, Mark J. ;

Gale, Davina ;

Forshew, Tim ;

Mahler-Araujo, Betania ;

Rajan, Sabrina ;

Humphray, Sean ;

Becq, Jennifer ;

Halsall, David ;

Wallis, Matthew ;

Bentley, David ;

Caldas, Carlos ;

Rosenfeld, Nitzan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (13) :1199-1209

[4] Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR [J].

Gevensleben, Heidrun ;

Garcia-Murillas, Isaac ;

Graeser, Monika K. ;

Schiavon, Gaia ;

Osin, Peter ;

Parton, Marina ;

Smith, Ian E. ;

Ashworth, Alan ;

Turner, Nicholas C. .

CLINICAL CANCER RESEARCH, 2013, 19 (12) :3276-3284

[5] Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance [J].

Gormally, Emmanuelle ;

Caboux, Elodie ;

Vineis, Paolo ;

Hainaut, Pierre .

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2007, 635 (2-3) :105-117

[6] HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J].

Gravalos, C. ;

Jimeno, A. .

ANNALS OF ONCOLOGY, 2008, 19 (09) :1523-1529

[7] High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number [J].

Hindson, Benjamin J. ;

Ness, Kevin D. ;

Masquelier, Donald A. ;

Belgrader, Phillip ;

Heredia, Nicholas J. ;

Makarewicz, Anthony J. ;

Bright, Isaac J. ;

Lucero, Michael Y. ;

Hiddessen, Amy L. ;

Legler, Tina C. ;

Kitano, Tyler K. ;

Hodel, Michael R. ;

Petersen, Jonathan F. ;

Wyatt, Paul W. ;

Steenblock, Erin R. ;

Shah, Pallavi H. ;

Bousse, Luc J. ;

Troup, Camille B. ;

Mellen, Jeffrey C. ;

Wittmann, Dean K. ;

Erndt, Nicholas G. ;

Cauley, Thomas H. ;

Koehler, Ryan T. ;

So, Austin P. ;

Dube, Simant ;

Rose, Klint A. ;

Montesclaros, Luz ;

Wang, Shenglong ;

Stumbo, David P. ;

Hodges, Shawn P. ;

Romine, Steven ;

Milanovich, Fred P. ;

White, Helen E. ;

Regan, John F. ;

Karlin-Neumann, George A. ;

Hindson, Christopher M. ;

Saxonov, Serge ;

Colston, Bill W. .

ANALYTICAL CHEMISTRY, 2011, 83 (22) :8604-8610

[8] Assessment of a HER2 scoring system for gastric cancer:: results from a validation study [J].

Hofmann, M. ;

Stoss, O. ;

Shi, D. ;

Buettner, R. ;

van de Vijver, M. ;

Kim, W. ;

Ochiai, A. ;

Rueschoff, J. ;

Henkel, T. .

HISTOPATHOLOGY, 2008, 52 (07) :797-805

[9] Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) [J].

Kurokawa, Y. ;

Sugimoto, N. ;

Miwa, H. ;

Tsuda, M. ;

Nishina, S. ;

Okuda, H. ;

Imamura, H. ;

Gamoh, M. ;

Sakai, D. ;

Shimokawa, T. ;

Komatsu, Y. ;

Doki, Y. ;

Tsujinaka, T. ;

Furukawa, H. .

BRITISH JOURNAL OF CANCER, 2014, 110 (05) :1163-1168

[10]

Mason J, 2012, EXPERT REV MOL DIAGN, V12, P511, DOI [10.1586/ERM.12.44, 10.1586/erm.12.44]

← 1 2 →